Exdensur Injection, Solution
Product Images NDC 0173-0927

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Exdensur (NDC 0173-0927). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Exdensur Spl Graphic 01)

An instructional diagram showing a prefilled syringe of Exdensur (depemokimab) 100 mg/mL injection, solution for subcutaneous use. The diagram details components before use including the clear cap, yellow needle guard, inspection window showing medication inside, stopper, and label with expiration date. After use, the clear cap with needle shield, stopper, yellow indicator visible upon injection completion, and expiration date label are shown.*

FDA Label Image

1. Pull Off The Clear Cap (Exdensur Spl Graphic 02)

An instructional illustration showing a hand holding a syringe with an orange arrow indicating the removal or insertion of a cap or needle cover from the syringe tip. The illustration focuses on preparing the syringe for subcutaneous injection.*

FDA Label Image

2. Position The Pen At The Injection Site And Press Firmly To Start The Injection (Exdensur Spl Graphic 03)

An instructional illustration showing a hand holding a prefilled injector pen aimed downward to administer a subcutaneous injection. The image highlights the pressing action with an orange arrow pointing down and an orange indicator light on the pen, suggesting activation for injection.*

FDA Label Image

3. Continue To Hold Down (Exdensur Spl Graphic 04)

An illustration showing a hand holding an injection device vertically, with an orange mark inside the device indicating dose delivery. Text next to the image states that the injection may take up to 20 seconds. This diagram demonstrates the proper timing for subcutaneous administration of an injection.*

FDA Label Image

Figure 2 (Exdensur Spl Graphic 05)

An instructional diagram showing a subcutaneous injection device before and after use. Before use, the syringe includes a gray needle cap, an inspection window for viewing medication inside, a stopper, a white finger grip, and a white plunger. After use, the gray needle cap is removed, and the automatic needle guard is activated and retracts to cover the needle, with the stopper still visible.*

FDA Label Image

1. Pull Off The Gray Needle Cap (Exdensur Spl Graphic 06)

An instructional illustration showing a hand holding a syringe with the needle cap being removed by the other hand, indicated by an orange arrow pointing upward. The image conveys the step of preparing an injection by removing the needle cap before use.*

FDA Label Image

2. Position The Syringe At The Injection Site (Exdensur Spl Graphic 07)

An instructional illustration showing a hand administering a subcutaneous injection at a 45-degree angle using a syringe, emphasizing proper injection technique for a solution injection like Exdensur (depemokimab).*

FDA Label Image

3. Start The Injection And Fully Press The White Plunger (Exdensur Spl Graphic 08)

An instructional illustration showing a hand using a syringe for a subcutaneous injection. A close-up inset highlights the importance of ensuring the syringe's white plunger is fully depressed during administration.*

FDA Label Image

4. Slowly Lift Thumb After Injection Completes (Exdensur Spl Graphic 09)

An instructional illustration depicting a hand administering a subcutaneous injection using a prefilled syringe. The syringe is being pressed against the skin at an angle, with an orange arrow indicating the direction of injection, suggesting the medication is being injected under the skin.*

FDA Label Image

Figure 3 (Exdensur Spl Graphic 10)

A Kaplan-Meier curve chart comparing probability of event (%) over time in weeks for Exdensur 100 mg subcutaneous injection versus placebo. The chart shows two survival curves with confidence intervals, along with number at risk at various time points for both Exdensur and placebo groups.*

FDA Label Image

Figure 4 (Exdensur Spl Graphic 11)

A graph depicting the probability of an event (%) over time in weeks, comparing Exdensur 100 mg subcutaneous injection to placebo. The plot includes two curves with shaded confidence intervals, showing the number of subjects at risk across different time points up to 52 weeks.*

FDA Label Image

Exdensur 100 mg Per mL Syringe Carton (Exdensur Spl Graphic 12)

Exdensur (depemokimab-ulaa) 100 mg/mL injection in a prefilled syringe for subcutaneous use. The label shows the proprietary name, generic name, strength, dosage form, and route. It includes contents of one single-dose 1 mL prefilled syringe along with prescribing and patient information. Labeler is GlaxoSmithKline LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.